Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal hidden social struggles in MS patients

NCT ID NCT02290587

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study used brain scans to understand why some people with multiple sclerosis have trouble with social thinking, like reading emotions or intentions. Researchers compared 35 MS patients to healthy volunteers using MRI while they performed social tasks. The goal was to see which brain areas are affected and how the brain tries to compensate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help explain why some MS patients struggle with social interactions, potentially guiding future therapies or support strategies.
What could go wrong
This is a small, observational study with only 35 participants, so findings may not apply broadly. It does not test any treatment, so no direct benefit for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Nov 2015

Finished

Mar 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 59 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (patient group): * Aged 18-59 years * Right handed * Fluent French speaker * MS diagnosis according to McDonald criteria (Polman et al., 2005). * Relapsing-remitting MS (RRMS) according to Lublin et al. (1996); * Having signed an informed consent (later than the day of inclusion and before any examination required by research) * Being affiliated to health insurance Inclusion Criteria (healthy control): * Aged 18-59 years * Right handed * Fluent French speaker * Having signed an informed consent (later than the day of inclusion and before any examination required by research) * Being affiliated to health insurance Exclusion Criteria (patient group): * Other progressive neurological disease; * psychiatric comorbidity including severe depression according to Diagnostic and Statistical Manual-IV (DSM-IV), * alcohol or other addiction to toxic, * Expanded Disability Status Scale (EDSS) \> 6; disabling visual or motor problems preventing participation to neuropsychological assessments, * relapse since less than one month, * change of disease-modifying therapy or psychotropic drug since less than one month, * Contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body, claustrophobia) or refusing MRI * Illiteracy, is unable to count or to read * Pregnant or breastfeeding women * Being under guardianship Exclusion Criteria (healthy control): * History of neurological disease; * family history of MS; * psychiatric comorbidity including severe depression according to DSM-IV; * alcohol or other toxic addiction; * psychotropic drugs; known cognitive complaint or neuropsychological affection; * Prior neuropsychological testing with the same tests less than one year * Contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body, claustrophobia) or refusing MRI * Illiteracy, is unable to count or to read * Pregnant or breastfeeding women * Being under guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.